Gossamer Bio, Inc.
GOSS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728117
No open-market purchases or sales by Gossamer Bio, Inc. insiders were filed in the last 90 days; 171 institutions reported holding it in 13F filings for Q2 2026, worth $60.8M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Market capClose on Nov 9, 2026
- $65.0M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −14 vs. previous quarter
- 171
- 13F valueReported value at the end of Q2 2026
- $60.8M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $48.5M
- −57.7% year over year
- Net income, FY2025
- -$170.4M
- No comparable prior period
- Free cash flow, FY2025
- -$171.3M
- No comparable prior period
- Revenue, Q2 FY2026
- $9.24M
- −19.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $170.4M (351.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 1.44M
- Shares sold short
- Change
- +198.5K
- +16.0% vs. previous
- Days to cover
- 5.12
- At average daily volume
Superinvestors holding GOSS, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Gossamer Bio, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
0.1%
Gossamer Bio, Inc.'s share of the portfolio
- Shares
- 4,974,041
- Value
- $818.7K
Latest insider trades
See all insider tradesOpen-market purchases and sales by Gossamer Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 (view filing) | Aug 19 | 1 day | Milligan SandraDirector | PPurchase | +26.1K | $1.92 | +$50.0K | +81.4%58.0K after | |
| Jun 25, 2024 (view filing) | Jun 24 | 1 day | Aranda RichardChief Medical Officer | SSale | −1.91K | $0.66 | −$1.26K | −1.0%196.9K after | |
| Jun 24, 2024 (view filing) | Jun 21 | 3 days | Hasnain FaheemPresident & CEO | PPurchase | +372.0K | $0.67 | +$249.2K | +7.4%5.41M after | |
| Jun 20, 2024 (view filing) | Jun 18 | 2 days | Giraudo BryanCOO/CFO | PPurchase | +100.0K | $0.59 | +$59.0K | +26.3%480.0K after | |
| Jun 20, 2024 (view filing) | Jun 17 | 3 days | Smith Robert Paul JRChief Commercial Officer | PPurchase | +25.0K | $0.60 | +$15.0K | New position25.0K after | |
| Mar 28, 2024 (view filing) | Mar 27 | 1 day | Christian WaageEVP, Tech Ops and Admin | SSale | −6.43K | $1.16 | −$7.46K | −1.1%585.9K after | |
| Mar 28, 2024 (view filing) | Mar 27 | 1 day | Giraudo BryanCOO/CFO | SSale | −6.43K | $1.16 | −$7.46K | −6.5%92.7K after | |
| Mar 28, 2024 (view filing) | Mar 27 | 1 day | Hasnain FaheemPresident & CEO | SSale | −23.2K | $1.16 | −$26.9K | −16.2%120.3K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Aranda RichardChief Medical Officer | SSale | −4.02K | $1.33 | −$5.34K | −2.0%198.8K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Peterson CarynEVP, Regulatory Affairs | SSale | −4.02K | $1.33 | −$5.34K | −7.5%49.8K after |
Top 10 13F holders, Q2 2026
See all 171 holdersThe largest institutional positions in Gossamer Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| D. E. Shaw & Co., Inc. | 40,959,285 | $6.74M | 0.00% | +40,569,854+10,417.7% | Added |
| 683 Capital Management, LLC | 39,198,868 | $6.45M | 0.59% | +34,198,868+684.0% | Added |
| DeepCurrents Investment Group LLC | 37,665,073 | $6.03M | 0.21% | +37,665,073 | New |
| Context Capital Management, LLC | 28,946,459 | $4.76M | 0.10% | +28,946,459 | New |
| Worth Venture Partners, LLC | 25,017,881 | $4.12M | 9.29% | +25,017,881 | New |
| AQR Capital Management LLC | 15,629,993 | $2.57M | 0.00% | +5,503,096+54.3% | Added |
| Gsa Capital Partners LLP | 14,986,947 | $2.47M | 0.16% | +11,732,714+360.5% | Added |
| Wolverine Asset Management LLC | 12,894,746 | $2.12M | 0.03% | +12,894,746 | New |
| Renaissance Technologies LLC | 11,629,896 | $1.91M | 0.00% | +10,412,028+854.9% | Added |
| Kalehua Capital Management LLC | 11,149,363 | $1.84M | 1.05% | +913,070+8.9% | Added |
Holders of 5% or more of GOSS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Gossamer Bio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G | 10.90%667.5K shares | – | Feb 9, 20243 filings | Nov 6, 2026 | SEC |
| 683 Capital Management, LLC | 13G | 9.99%49.9M shares | +6.09 ppfrom 3.90% | Mar 2, 20263 filings | Jun 11, 2026 | SEC |
| Context Capital Management, LLC | 13G | 9.90%48.8M shares | New | Jun 9, 20261 filing | Jun 9, 2026 | SEC |
| DeepCurrents Investment Group LLC | 13G | 7.70%37.7M shares | New | Jun 11, 20261 filing | Jun 11, 2026 | SEC |
| Opaleye Management Inc. | 13G/A | 6.98%427.0K shares | +1.88 ppfrom 5.10% | Jul 29, 20262 filings | Nov 6, 2026 | SEC |